Pacira BioSciences, Inc.
PCRXHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Pacira BioSciences, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. At a $1.05B market cap, Pacira BioSciences, Inc. ranks as a small-cap company within healthcare. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.
Market Cap
$1.05B
Beta
0.27
P/E (TTM)
75.29
P/E (Fwd)
7.64
EPS (TTM)
$0.35
EPS (Fwd)
$3.45
ROE
2.1%
ROA
1.5%
Cash
$251.0M
Total Debt
$412.1M
Free CF
$98.3M
52W Change
0.2%
Annual Financials
Cash vs Debt
Where PCRX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PCRX finished 11.82% above its 150-day moving average ($23.77) and 11.68% above its 200-day moving average ($23.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PCRX overbought or oversold?
At the September 3, 2026 close, PCRX's RSI(14) was 83.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $251.0M in cash, though total debt stands at $412.1M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $98.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 2.1% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.5% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $666.8M (2022) to $726.4M (2025).
With a beta below 0.7, Pacira BioSciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Pacira BioSciences, Inc.'s trajectory.